COMPANY PROFILE // THE 014 REPORT
Ionis Pharmaceuticals Inc.
IONS (Nasdaq) · Formerly: ISIS PHARMACEUTICALS INC
Assembled from 5 government sources in 0.3 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
- AmberLEI 549300SI4ZGLG0BLUZ92 registration status is LAPSED (last update 2022-03-18): the legal-entity record has not been renewed.
✓ SEC filings✓ LEI✓ State registrationpossible match✓ Lobbying registrationpossible match✗ SAM registration✗ IRS return✗ Website
No SAM registration, no IRS return, no website on record.
IONIS PHARMACEUTICALS INC is an SEC-registered operating company in pharmaceutical preparations, incorporated in CA, based in Carlsbad, CA; listed as IONS (Nasdaq).[source] It reported revenue of $943.7 million for the fiscal year ended 2025-12-31.[source] It has filed 198 documents with the SEC in the last 12 months; the latest is Form 4, filed 2026-11-13.[source] 2 lobbying disclosure filings name a client with this company's exact name (possible match).[source] Its largest institutional holders on 13F filings are FMR LLC, Capital World Investors, BlackRock, Inc. (as of 2026-06-30).[source] Seraphix flags 1 item from these records: LEI 549300SI4ZGLG0BLUZ92 registration status is LAPSED (last update 2022-03-18).[source]
- red0
- amber1
- info0
- FMR LLC$1.95B
- Capital World Investors$1.72B
- BlackRock, Inc.$848.8M
- VANGUARD PORTFOLIO MANAGEMENT LLC$623.2M
- WELLINGTON MANAGEMENT GROUP LLP$606.7M
- VANGUARD CAPITAL MANAGEMENT LLC$571.8M
- TWO SIGMA INVESTMENTS, LP$495.7M
- ROYAL BANK OF CANADA$490.2M
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Officers and directors (Forms 3, 4, 5)
- BENNETT C FRANK · EVP, Chief Scientific Officer (Officer) · latest Form 4 2026-03-05 · filing · LinkedIn search
- Baroldi Joseph · EVP, Chief Business Officer (Officer) · latest Form 4 2026-03-05 · filing · LinkedIn search
- Birchler Brian · EVP, Corp and Development Ops (Officer) · latest Form 4 2026-03-03 · filing · LinkedIn search
- Devers Shannon L. · EVP, Chief Human Resources Ofc (Officer) · latest Form 4 2026-03-05 · filing · LinkedIn search
- Geary Richard S · EVP, Chief Development Officer (Officer) · latest Form 4 2025-11-07 · filing · LinkedIn search
- HOUGEN ELIZABETH L · EVP, Finance & CFO (Officer) · latest Form 4 2026-03-18 · filing · LinkedIn search
- Jenne Kyle · EVP, Chf GL Pdt Str Ofcr (Officer) · latest Form 4 2026-03-11 · filing · LinkedIn search
- Kordasiewicz Holly B. · EVP, Chief Development Officer (Officer) · latest Form 4/A 2026-01-20 · filing · LinkedIn search
- Monia Brett P · Chief Executive Officer (Director,Officer) · latest Form 4 2026-03-11 · filing · LinkedIn search
- O'NEIL PATRICK R. · EVP CLO & General Counsel (Officer) · latest Form 4 2026-03-11 · filing · LinkedIn search
- Schneider Eugene · EVP, Chf Clinical Develop Ofcr (Officer) · latest Form 4 2026-03-23 · filing · LinkedIn search
- Swayze Eric · EVP Research (Officer) · latest Form 4 2026-03-03 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 25 CLEAR, 1 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0000874015 | source |
| LEI | 549300SI4ZGLG0BLUZ92 | source |
| EIN | 33-0336973 | source |
| California SOS entity | 1387870-05-251-1169570 | record |
| Connecticut business ID | 3170597 | record |
| LDA clientpossible match | 61063 | record |
| LDA clientpossible match | 61064 | record |
| Business address (SEC) | 2855 GAZELLE COURT, CARLSBAD, CA, 92010 | source |
Does not exist in the records we hold: UEI, NY DOS ID, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2022-03-18 · in -1,710 days · LEI next renewal (549300SI4ZGLG0BLUZ92)
- 2027-03-01 · in 99 days · Next 10-K due (period ended 2026-12-31; Large accelerated filer) (computed from the fiscal year end and filer status)
- 2027-05-10 · in 169 days · Next 10-Q due (period ended 2027-03-31; Large accelerated filer) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2834 (pharmaceutical preparations): 568 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- PFIZER INC · 124 SEC filings in 12 months · $25.74B federal (possible match)
- Merck & Co., Inc. · 150 SEC filings in 12 months · $13.51B federal (possible match)
- ABBOTT LABORATORIES · 118 SEC filings in 12 months · 1 flag · $2.64B federal (possible match)
- ASTRAZENECA PLC · 140 SEC filings in 12 months · $602.8M federal (possible match)
- TEVA PHARMACEUTICAL INDUSTRIES LTD · 168 SEC filings in 12 months · $77.6M federal (possible match)
- NOVARTIS AG · 34 SEC filings in 12 months · $41.9M federal (possible match)
- Spero Therapeutics, Inc. · 41 SEC filings in 12 months · 4 flags · $39.5M federal (possible match)
- Grifols SA · 18 SEC filings in 12 months · $22.5M federal (possible match)
- SCYNEXIS INC · 54 SEC filings in 12 months · 3 flags · $18.5M federal (possible match)
- Ensysce Biosciences, Inc. · 45 SEC filings in 12 months · 3 flags · $15.1M federal (possible match)
- UNITED THERAPEUTICS Corp · 454 SEC filings in 12 months · 2 flags · $6.8M federal (possible match)
- Zoetis Inc. · 144 SEC filings in 12 months · 1 flag · $6.7M federal (possible match)
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- AbCellera Biologics Inc. · Hayden Michael R
- Artiva Biotherapeutics, Inc. · Elizabeth L. Hougen
- COGNITION THERAPEUTICS INC · Brett P. Monia, Ph.D.
- CYPHERPUNK TECHNOLOGIES INC. · LOSCALZO JOSEPH
- Encompass Health Corp · HERMAN JOAN E
- HOLOGIC INC · HANTSON LUDWIG
- Mersana Therapeutics, Inc. · Diaz Allene M.
- Pacira BioSciences, Inc. · YANG MICHAEL J.
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-09 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-09 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-10-23 filing 8-K items 7.01,8.01,9.01 · SEC EDGAR
- 2026-10-21 filing 8-K items 7.01,8.01,9.01 · SEC EDGAR
- 2026-10-16 filing 144 · SEC EDGAR
- 2026-09-23 filing 8-K items 7.01,8.01,9.01 · SEC EDGAR
- 2026-09-04 filing 8-K items 7.01,8.01,9.01 · SEC EDGAR
- 2026-09-04 filing 8-K items 7.01,8.01,9.01 · SEC EDGAR
- 2026-07-31 filing S-8 · SEC EDGAR
- 2026-07-29 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-07-29 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-07-10 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-07-09 filing 8-K items 7.01,8.01,9.01 · SEC EDGAR
- 2026-07-07 filing 144 · SEC EDGAR
- 2026-07-07 filing 144 · SEC EDGAR
- 2026-07-07 filing 144 · SEC EDGAR
- 2026-07-01 filing 144 · SEC EDGAR
- 2026-06-26 filing 144 · SEC EDGAR
- 2026-06-26 filing 144 · SEC EDGAR
- 2026-06-26 filing 144 · SEC EDGAR
- 2026-06-25 filing 144 · SEC EDGAR
- 2026-06-24 filing 8-K items 7.01,8.01,9.01 · SEC EDGAR
- 2026-06-15 filing 144 · SEC EDGAR
- 2026-06-12 filing 144 · SEC EDGAR
- 2026-06-12 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2026-06-08 officer change 8-K items 5.02,5.07,7.01,9.01 · SEC EDGAR
- 2026-06-01 filing 144 · SEC EDGAR
- 2026-05-28 filing 8-K items 7.01,8.01,9.01 · SEC EDGAR
- 2026-05-13 filing 144 · SEC EDGAR
- 2026-05-04 filing 144 · SEC EDGAR
162 earlier entries
- 2026-04-29 filing Quarterly report (10-Q)
- 2026-04-29 filing 8-K items 2.02,9.01
- 2026-04-28 filing 144
- 2026-04-23 filing ARS
- 2026-04-23 filing DEFA14A
- 2026-04-23 filing Proxy statement
- 2026-04-21 filing 8-K items 7.01,8.01,9.01
- 2026-04-16 filing 144
- 2026-04-16 filing 144
- 2026-04-16 filing 144
- 2026-03-31 filing 144
- 2026-03-24 filing 144/A
- 2026-03-19 filing 144
- 2026-03-16 filing 144
- 2026-03-10 filing 144
- 2026-03-09 filing 144
- 2026-03-09 officer change 8-K items 5.02,7.01,9.01
- 2026-03-03 filing 144/A
- 2026-03-03 filing 144
- 2026-03-03 filing 144
- 2026-03-03 filing 144
- 2026-03-03 filing 144
- 2026-03-03 filing 144
- 2026-02-26 filing Annual report (10-K)
- 2026-02-25 filing 8-K items 2.02,9.01
- 2026-02-13 filing 144
- 2026-02-11 filing 144
- 2026-02-06 filing 144
- 2026-02-02 filing 144
- 2026-01-30 filing 144
- 2026-01-30 filing 144
- 2026-01-30 filing 144
- 2026-01-30 filing 144
- 2026-01-30 filing 144
- 2026-01-30 filing 144
- 2026-01-30 filing 144
- 2026-01-30 filing 144
- 2026-01-23 filing 144/A
- 2026-01-22 filing 144
- 2026-01-21 filing 144
- 2026-01-16 filing 144
- 2026-01-16 filing 144
- 2026-01-16 filing 144
- 2026-01-16 filing 144
- 2026-01-16 filing 144
- 2026-01-16 filing 144
- 2026-01-16 filing 144
- 2026-01-16 filing 144
- 2026-01-16 filing 144
- 2026-01-16 filing 144
- 2026-01-16 filing 144
- 2026-01-12 filing 8-K items 2.02,9.01
- 2026-01-07 filing 144
- 2026-01-07 filing 8-K items 7.01,8.01,9.01
- 2026-01-06 insider First Form 3/4/5 on record for Kordasiewicz Holly B. (EVP, Chief Development Officer)
- 2026-01-02 filing 144
- 2025-12-01 filing 144/A
- 2025-12-01 filing 144
- 2025-11-25 filing 144
- 2025-11-25 filing 144
- 2025-11-19 filing 144
- 2025-11-17 filing 8-K items 1.01,2.03,3.02,8.01,9.01
- 2025-11-10 filing 8-K items 7.01,8.01,9.01
- 2025-11-03 filing 8-K/A items 1.01,9.01
- 2025-10-31 filing 144
- 2025-10-31 filing 144
- 2025-10-30 filing 144
- 2025-10-29 filing Quarterly report (10-Q)
- 2025-10-29 filing 8-K items 2.02,9.01
- 2025-10-15 filing 144
- 2025-10-15 filing 144
- 2025-10-14 filing 144
- 2025-10-06 filing 144
- 2025-10-06 filing 144
- 2025-10-06 filing 144
- 2025-10-02 filing 144
- 2025-10-02 filing 144
- 2025-10-01 filing 144
- 2025-10-01 filing 144
- 2025-10-01 insider First Form 3/4/5 on record for HOUGEN ELIZABETH L (EVP, Finance & CFO)
- 2025-09-30 filing 144
- 2025-09-30 filing 144
- 2025-09-22 filing 8-K items 7.01,8.01,9.01
- 2025-09-04 insider First Form 3/4/5 on record for Devers Shannon L. (EVP, Chief Human Resources Ofc)
- 2025-09-04 insider First Form 3/4/5 on record for Swayze Eric (EVP Research)
- 2025-09-03 filing 144
- 2025-09-03 filing 144
- 2025-09-03 filing 144
- 2025-09-03 filing 144
- 2025-09-03 filing 144
- 2025-09-03 filing 144
- 2025-09-03 filing 144
- 2025-09-03 filing 144
- 2025-09-03 insider First Form 3/4/5 on record for O'NEIL PATRICK R. (EVP CLO & General Counsel)
- 2025-09-02 filing 144
- 2025-09-02 filing 144
- 2025-09-02 filing 144
- 2025-09-02 filing 144
- 2025-09-02 filing 144
- 2025-09-02 filing 8-K items 7.01,8.01,9.01
- 2025-08-29 filing 144
- 2025-08-21 filing 8-K items 7.01,8.01,9.01
- 2025-08-20 insider First Form 3/4/5 on record for BENNETT C FRANK (EVP, Chief Scientific Officer)
- 2025-08-18 filing 144
- 2025-08-06 filing 144
- 2025-08-06 insider First Form 3/4/5 on record for Geary Richard S (EVP, Chief Development Officer)
- 2025-08-05 filing 144
- 2025-08-05 insider First Form 3/4/5 on record for Schneider Eugene (EVP, Chf Clinical Develop Ofcr)
- 2025-08-04 filing 144
- 2025-07-30 filing 144
- 2025-07-30 filing S-8
- 2025-07-30 filing Quarterly report (10-Q)
- 2025-07-30 filing 8-K items 2.02,9.01
- 2025-07-15 insider First Form 3/4/5 on record for Monia Brett P (Chief Executive Officer)
- 2025-07-02 insider First Form 3/4/5 on record for BERTHELSEN SPENCER R (Director)
- 2025-07-02 insider First Form 3/4/5 on record for Diaz Allene M. (Director)
- 2025-07-02 insider First Form 3/4/5 on record for HERMAN JOAN E (Director)
- 2025-07-02 insider First Form 3/4/5 on record for KLEIN JOSEPH III (Director)
- 2025-07-02 insider First Form 3/4/5 on record for LOSCALZO JOSEPH (Director)
- 2025-07-02 insider First Form 3/4/5 on record for PARSHALL B LYNNE (Director)
- 2025-07-02 insider First Form 3/4/5 on record for WENDER JOSEPH H (Director)
- 2025-07-02 insider First Form 3/4/5 on record for YANG MICHAEL J. (Director)
- 2025-06-12 officer change 8-K items 5.02,9.01
- 2025-06-10 filing 8-K items 5.07,9.01
- 2025-05-19 filing 8-K items 8.01,9.01
- 2025-05-02 insider First Form 3/4/5 on record for Hayden Michael R (Director)
- 2025-04-30 filing Quarterly report (10-Q)
- 2025-04-30 filing 8-K items 2.02,9.01
- 2025-04-25 filing ARS
- 2025-04-25 filing DEFA14A
- 2025-04-25 filing Proxy statement
- 2025-04-17 insider First Form 3/4/5 on record for Baroldi Joseph (EVP, Chief Business Officer)
- 2025-04-17 insider First Form 3/4/5 on record for Birchler Brian (EVP, Corp and Development Ops)
- 2025-04-17 insider First Form 3/4/5 on record for Jenne Kyle (EVP, Chf GL Pdt Str Ofcr)
- 2025-04-16 filing 144
- 2025-04-16 filing 144
- 2025-04-16 filing 144
- 2025-03-12 filing 8-K items 1.01,9.01
- 2025-03-11 filing 144
- 2025-02-19 filing Annual report (10-K)
- 2025-02-19 filing 8-K items 2.02,9.01
- 2025-02-04 filing 144/A
- 2025-02-04 filing 144
- 2025-02-04 filing 144
- 2025-01-31 filing 144
- 2025-01-31 filing 144
- 2025-01-31 filing 144
- 2025-01-31 filing 144
- 2025-01-31 filing 144
- 2025-01-31 filing 144
- 2025-01-31 filing 144
- 2025-01-16 filing 144
- 2025-01-16 filing 144
- 2025-01-16 filing 144
- 2025-01-16 filing 144
- 2025-01-16 filing 144
- 2025-01-16 filing 144
- 2025-01-16 filing 144
- 2025-01-16 filing 144
- 2025-01-16 filing 144
- 2025-01-16 filing 144
- 2015-12-18 name change Name changed from ISIS PHARMACEUTICALS INC
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-09 (within 30 days) 10-Q filed (QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D))
- 2026-11-09 (within 30 days) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-10-23 (within 30 days) 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-10-21 (older) 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-09-23 (older) 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-09-14 (older) Form 5500 received for plan year ending 2025-12-31 (plan no. 001)
- 2026-09-04 (older) 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-09-04 (older) 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-21; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:IONS The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
12 possible matches held apart, matched by name only, not counted above; 6 records under a former name, shown apart.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 874015 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | IONS / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| LEI (root of the ownership tree) | 549300SI4ZGLG0BLUZ92 | id:lei-family: legal entity in this company's GLEIF ownership tree (LEI 549300SI4ZGLG0BLUZ92) | GLEIF |
| EIN | 330336973 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0000874015 | SEC EDGAR / IRS |
| CUSIP | 462222100 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0000874015 | SEC EDGAR |
possible match: matched by name only, not merged (6)
Identifiers carried by records that share the company's exact name. Not merged into the identity above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| LDA client id | 61063 (IONIS PHARMACEUTICALS, INC. (lobbying via IONIS PHARMACEUTICALS, INC.)) | name-exact:legal-name: same registered legal name as 'IONIS PHARMACEUTICALS INC' | Lobbying Disclosure Act (LDA) |
| LDA client id | 61064 (IONIS PHARMACEUTICALS, INC. (lobbying via LMH STRATEGIC SOLUTIONS)) | name-exact:legal-name: same registered legal name as 'IONIS PHARMACEUTICALS INC' | Lobbying Disclosure Act (LDA) |
| EPA FRS id | 110072319370 (IONIS PHARMACEUTICALS) | name-exact: exact name match to 'IONIS PHARMACEUTICALS INC' (no other entity shares the name) | EPA ECHO facilities |
| EPA FRS id | 110072319887 (IONIS PHARMACEUTICALS) | name-exact: exact name match to 'IONIS PHARMACEUTICALS INC' (no other entity shares the name) | EPA ECHO facilities |
| EPA FRS id | 110022527817 (IONIS PHARMACEUTICALS INC) | name-exact:legal-name: same registered legal name as 'IONIS PHARMACEUTICALS INC' | EPA ECHO facilities |
| EPA FRS id | 110072038445 (IONIS PHARMACEUTICALS, INC.) | name-exact:legal-name: same registered legal name as 'IONIS PHARMACEUTICALS INC' | EPA ECHO facilities |
former name (shown apart, not merged) (6)
- former nameISIS PHARMACEUTICALS · EPA ECHO facilities
- former nameISIS PHARMACEUTICALS · EPA ECHO facilities
- former nameISIS PHARMACEUTICALS INC · EPA ECHO facilities
- former nameISIS PHARMACEUTICALS, INC · EPA ECHO facilities
- former nameISIS PHARMACEUTICALS, INC · EPA ECHO facilities
- former nameISIS PHARMACEUTICALS, INC · EPA ECHO facilities
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Revenue (fiscal year ended 2025-12-31) | $943,711,000 | 2025-12-31 | 10-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax | as filed | 2026-11-21 11:44 UTC | Report an error |
| Net income (loss) (fiscal year ended 2025-12-31) | -$381,387,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-21 11:44 UTC | Report an error |
| Total assets (at 2025-12-31) | $3,523,836,000 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-21 11:44 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | $489,089,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-21 11:44 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $372,260,000 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-21 11:44 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-13 | SEC EDGAR company profile | as filed | 2026-11-21 11:44 UTC | Report an error |
| SIC industry | 2834 Pharmaceutical Preparations | 2026-11-13 | SEC EDGAR company profile | as filed | 2026-11-21 11:44 UTC | Report an error |
| State of incorporation | CA | 2026-11-13 | SEC EDGAR company profile | as filed | 2026-11-21 11:44 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-13 | SEC EDGAR company profile | as filed | 2026-11-21 11:44 UTC | Report an error |
| Business address | 2855 GAZELLE COURT, CARLSBAD, CA, 92010 | 2026-11-13 | SEC EDGAR company profile | as filed | 2026-11-21 11:44 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-13 | SEC EDGAR company profile | as filed | 2026-11-21 11:44 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | -$268,583,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-21 11:44 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $51,444,000 | 2025-12-31 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | as filed | 2026-11-21 11:44 UTC | Report an error |
| Long-term debt (at 2025-12-31) | $1,812,405,000 | 2025-12-31 | 10-K, XBRL LongTermDebt | as filed | 2026-11-21 11:44 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $271,892,000 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-21 11:44 UTC | Report an error |
| Plan (pension, plan no. 001) | IONIS PHARMACEUTICALS 401(K) PLAN: 1,628 participants, assets $390,345,133 | 2025-12-31 | DOL EBSA Form 5500 public datasets (dataset) | as filed | 2026-11-21 11:44 UTC | Report an error |
| Plan (welfare, plan no. 501) | IONIS PHARMACEUTICALS, INC. HEALTH AND WELFARE PLAN: 1,243 participants | 2025-12-31 | DOL EBSA Form 5500 public datasets (dataset) | as filed | 2026-11-21 11:44 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-09 · accession 0000874015-26-000271
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Revenue | $242,721,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-09 | 0000874015-26-000271 | 2026-11-21 11:44 UTC | Report an error |
| Net income (loss) | -$109,971,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-09 | 0000874015-26-000271 | 2026-11-21 11:44 UTC | Report an error |
| Interest expense | $4,628,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-09 | 0000874015-26-000271 | 2026-11-21 11:44 UTC | Report an error |
| Cash and cash equivalents | $296,303,000 | at 2026-09-30 | 10-Q | 2026-11-09 | 0000874015-26-000271 | 2026-11-21 11:44 UTC | Report an error |
| Contract liabilities, current | $70,203,000 | at 2026-09-30 | 10-Q | 2026-11-09 | 0000874015-26-000271 | 2026-11-21 11:44 UTC | Report an error |
| Contract liabilities, noncurrent | $48,755,000 | at 2026-09-30 | 10-Q | 2026-11-09 | 0000874015-26-000271 | 2026-11-21 11:44 UTC | Report an error |
| Debt due in the next 12 months (from an earlier report) | $443,157,000 | at 2025-12-31 | 10-K | 2026-02-26 | 0000874015-26-000115 | 2026-11-21 11:44 UTC | Report an error |
| Debt due in year 2 (from an earlier report) | $18,737,000 | at 2025-12-31 | 10-K | 2026-02-26 | 0000874015-26-000115 | 2026-11-21 11:44 UTC | Report an error |
| Debt due in year 3 (from an earlier report) | $580,091,000 | at 2025-12-31 | 10-K | 2026-02-26 | 0000874015-26-000115 | 2026-11-21 11:44 UTC | Report an error |
| Debt due in year 4 (from an earlier report) | $60,000 | at 2025-12-31 | 10-K | 2026-02-26 | 0000874015-26-000115 | 2026-11-21 11:44 UTC | Report an error |
| Debt due in year 5 (from an earlier report) | $770,060,000 | at 2025-12-31 | 10-K | 2026-02-26 | 0000874015-26-000115 | 2026-11-21 11:44 UTC | Report an error |
| Debt due after year 5 (from an earlier report) | $300,000 | at 2025-12-31 | 10-K | 2026-02-26 | 0000874015-26-000115 | 2026-11-21 11:44 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-09 Filing 10-Q filed (QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D))
- 2026-11-09 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-10-23 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-10-21 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-09-23 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-09-14 Filing Form 5500 received for plan year ending 2025-12-31 (plan no. 001)
- 2026-09-04 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-09-04 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-07-31 Filing S-8 filed
- 2026-07-29 Filing 10-Q filed (IONIS PHARMACEUTICALS, INC. 10-Q 06-30-2026)
- 2026-07-29 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-07-10 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-07-09 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-06-25 Filing Form 5500 received for plan year ending 2025-12-31 (plan no. 501)
- 2026-06-24 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-06-12 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-06-11 Record latest certified decision date in the file
- 2026-06-08 Filing 8-K filed: Item 5.02 officer or director change; Item 5.07 shareholder vote; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-05-28 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-05-13 Record earliest certified decision date in the file
- 2026-04-29 Filing 10-Q filed (IONIS PHARMACEUTICALS, INC. 10-Q 03-31-2026)
- 2026-04-29 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-04-23 Filing ARS filed
- 2026-04-23 Filing DEFA14A filed
- 2026-04-23 Filing DEF 14A filed
6 earlier entries
- 2026-04-21 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-03-09 Filing 8-K filed: Item 5.02 officer or director change; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-02-26 Filing 10-K filed (IONIS PHARMACEUTICALS, INC. 10-K 12-31-2025)
- 2026-02-25 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2015-01-01 Record plan effective date: IONIS PHARMACEUTICALS, INC. HEALTH AND WELFARE PLAN
- 1991-01-01 Record plan effective date: IONIS PHARMACEUTICALS 401(K) PLAN
8-K item text, as filed (excerpts)
- 2026-11-09 8-K Item 2.02
Results of Operations and Financial Condition. On November 9, 2026, Ionis Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended September 30, 2026. In addition to disclosing results that are determined in accordance with Generally Accepted Accounting Principles (“GAAP”), the Company also discloses pro forma or non-GAAP results of operations, which are adjusted from GAAP to exclude non-cash compensation expense related to equity awards and the related tax effects. The Company is presenting pro forma information excluding non-cash compensation expense related to equity awards and the related tax effects because the… the 8-K · retrieved 2026-11-21 11:44 UTC - 2026-10-23 8-K Item 7.01
Regulation FD Disclosure. On October 23, 2026, Ionis Pharmaceuticals, Inc. (“Ionis”) issued a press release reporting that its partner, Roche, announced late-breaking oral presentation data from the ongoing Phase 3 IMAgINATION study in adults with primary IgA nephropathy (“IgAN”) receiving optimized standard of care, demonstrating that investigational sefaxersen achieved a statistically significant and clinically meaningful 43.1% reduction in proteinuria (95% confidence interval [CI]: 32.5 - 52.0, P<0.0001), relative to placebo at 37 weeks, as measured by 24-hour urine protein-to-creatinine ratio (“UPCR”). The information in this Item 7.01 and the exhibit attached hereto shall not be deemed… the 8-K · retrieved 2026-11-21 11:44 UTC - 2026-10-23 8-K Item 8.01
Other Events. On October 23, 2026, Ionis’ partner, Roche, announced late-breaking oral presentation data from the ongoing Phase 3 IMAgINATION study in adults with primary IgAN receiving optimized standard of care, demonstrating that investigational sefaxersen achieved a statistically significant and clinically meaningful 43.1% reduction in proteinuria (95% confidence interval [CI]: 32.5 - 52.0, P<0.0001), relative to placebo at 37 weeks, as measured by 24-hour UPCR. Proteinuria is a key indicator of kidney damage and a reduction in UPCR is strongly associated with the preservation of long-term kidney function. Results presented at the American Society of Nephrology Kidney Week 2026 also… the 8-K · retrieved 2026-11-21 11:44 UTC - 2026-10-21 8-K Item 7.01
Regulation FD Disclosure. On October 20, 2026, Ionis Pharmaceuticals, Inc. (“Ionis”) issued a press release reporting that its partner, GSK, announced that the U.S. Food and Drug Administration (“FDA”) has approved HIBSAGO™ (bepirovirsen) for the treatment of chronic hepatitis B (“CHB”) virus infection in combination with nucleos(t)ide analogue reverse transcriptase inhibitor (“NrtI”) therapy in adult patients without cirrhosis, receiving Nrtl therapy for at least 6 months, who have suppressed HBV deoxyribonucleic acid (“DNA”), and with hepatitis B virus (“HBV”) surface antigen (“HBsAg”) levels ≤3000 IU/ml, as determined by an FDA-authorized test. A copy of the press release is furnished as… the 8-K · retrieved 2026-11-21 11:44 UTC - 2026-10-21 8-K Item 8.01
Other Events. On October 20, 2026, Ionis reported that its partner, GSK, announced that the FDA has approved HIBSAGO™ (bepirovirsen) for the treatment of CHB virus infection in combination with NrtI therapy in adult patients without cirrhosis, receiving Nrtl therapy for at least 6 months, who have suppressed HBV DNA, and with HBsAg levels ≤3000 IU/ml, as determined by an FDA-authorized test. GSK licensed bepirovirsen from Ionis and collaborated with them on its development. Bepirovirsen is a first in class RNA-targeted medicine that offers unprecedented functional cure rates compared to current standard of care. The approval was granted under FDA priority review and Breakthrough Therapy… the 8-K · retrieved 2026-11-21 11:44 UTC - 2026-09-23 8-K Item 7.01
Regulation FD Disclosure. On September 23, 2026, Ionis Pharmaceuticals, Inc. (“Ionis”) issued a press release announcing that Ionis and its partner, Roche Holding Ltd. (“Roche”), reported positive prespecified interim results from the ongoing Phase 3 IMAgINATION study evaluating investigational sefaxersen in adults with primary IgA nephropathy (“IgAN”). A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section… the 8-K · retrieved 2026-11-21 11:44 UTC - 2026-09-23 8-K Item 8.01
Other Events. On September 23, 2026, Ionis and its partner, Roche, announced positive prespecified interim results from the ongoing Phase 3 IMAgINATION study evaluating investigational sefaxersen in adults with IgAN. The study met its primary endpoint with sefaxersen achieving statistically significant and clinically meaningful improvements in proteinuria reduction, compared to placebo at 37 weeks, as measured by 24-hour urine protein-to-creatinine ratio (“UPCR”). Proteinuria is a key indicator of kidney damage, and a reduction in UPCR is strongly associated with the preservation of long-term kidney function. Sefaxersen is a once-monthly subcutaneous injection designed to enable… the 8-K · retrieved 2026-11-21 11:44 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
POSSIBLE MATCHES · NAME ONLY6. Lobbying (LDA)
2 lobbying records carry this company's exact name, hiring 2 lobbying firms. These are possible matches until the accuracy score, so they are not counted in the headline.
possible match: matched by name only, not merged (2)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchIONIS PHARMACEUTICALS, INC. (lobbying via IONIS PHARMACEUTICALS, INC.) · exact legal name · sx:lda:61063 Compare
- possible matchIONIS PHARMACEUTICALS, INC. (lobbying via LMH STRATEGIC SOLUTIONS) · exact legal name · sx:lda:61064 Compare
POSSIBLE MATCHES · GROUPED BY SOURCE8. Enforcement by agency
EPA ECHO facilities (4)
possible match: matched by name only, not merged (4)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchIONIS PHARMACEUTICALS · exact name match to 'IONIS PHARMACEUTICALS INC' (no other entity shares the name) · sx:epa:110072319370 Compare
- possible matchIONIS PHARMACEUTICALS · exact name match to 'IONIS PHARMACEUTICALS INC' (no other entity shares the name) · sx:epa:110072319887 Compare
- possible matchIONIS PHARMACEUTICALS INC · exact legal name · sx:epa:110022527817 Compare
- possible matchIONIS PHARMACEUTICALS, INC. · exact legal name · sx:epa:110072038445 Compare
Each record's own page holds its date and the agency document. Matched by exact name only; none of these is counted in the headline.
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | $1,953,067,764 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:44 UTC | Report an error |
| 2 | Capital World Investors | $1,718,152,930 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:44 UTC | Report an error |
| 3 | BlackRock, Inc. | $848,772,532 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:44 UTC | Report an error |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | $623,182,054 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:44 UTC | Report an error |
| 5 | WELLINGTON MANAGEMENT GROUP LLP | $606,680,694 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:44 UTC | Report an error |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | $571,799,597 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:44 UTC | Report an error |
| 7 | TWO SIGMA INVESTMENTS, LP | $495,748,197 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:44 UTC | Report an error |
| 8 | ROYAL BANK OF CANADA | $490,209,000 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:44 UTC | Report an error |
| 9 | STATE STREET CORP | $343,710,098 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:44 UTC | Report an error |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | $294,752,810 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:44 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
GLEIF OWNERSHIP TREE · ID TIER11. Subsidiaries
1 legal entity in the company's GLEIF ownership tree, joined by LEI (an official identifier).
- Ionis Pharmaceuticals, Inc. · LEI 549300SI4ZGLG0BLUZ92 · root
Exhibit 21 subsidiaries: not held yet.
DOL H-1B (LCA) · WARN NOT HELD12. Labor
Unconfirmed: these labor figures (positions, worksite states, certified LCAs later withdrawn) are as read from DOL's quarterly LCA disclosure file. Seraphix's independent second check of them is not finished (11-19); they are shown as filed, not as verified.
WARN layoff notices: not held yet.
POSSIBLE MATCHES · LICENCES, PERMITS, CITY AND STATE RECORDS13. Permits and local records
6 state and city records carry this company's exact name, from 5 sources. Possible matches only.
State licences (2)
possible match: matched by name only, not merged (2)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchIONIS PHARMACEUTICALS · exact name match to 'IONIS PHARMACEUTICALS INC' (no other entity shares the name) · sx:elic:ctcred:2688994 Compare
- possible matchIONIS PHARMACEUTICALS, INC. · exact legal name · sx:elic:ctcred:2708246 Compare
California business registrations (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchIonis Pharmaceuticals, Inc. · exact legal name · sx:cabiz:sf:1387870-05-251-1169570 Compare
Connecticut business registrations (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchIONIS PHARMACEUTICALS, INC. · exact legal name · sx:ctsos:3170597 Compare
ClinicalTrials.gov (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchIonis Pharmaceuticals, Inc. · exact legal name · sx:ctgov:h671c33e2587fbc2b Compare
City licences (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchIONIS PHARMACEUTICALS INC. · exact legal name · sx:mwlic:kc:bl-731812480 Compare
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/874015.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0000874015. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.